AChE/BChE-IN-36
AChE/BChE-IN-36 is a dual acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitor with blood-brain barrier permeability. AChE/BChE-IN-36 mediates blood-brain barrier transport through specific interactions with choline transporters. AChE/BChE-IN-36 can be used for the research of Alzheimer's disease.
For research use only. We do not sell to patients.
- Formula: C24H30BrN3
- Molecular Weight:440.42
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
hAChE 3.14 nM (IC50) |
eqBCHE 24.5 nM (IC50) |
electric eel AChE 11.54 nM (IC50) |
In Vitro
AChE/BChE-IN-36 (Compound C4) potently inhibits eeAChE, hAChE and eqBChE, with IC50 values of 11.54 nM, 3.14 nM and 24.50 nM, respectively[1].
AChE/BChE-IN-36 (5 μg/mL; 0-300 min) exhibits stronger blood-brain barrier (BBB) permeability in the bEnd.3 cell Transwell model, with a Papp of 19.58 × 10-6 cm/s[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
Molecular Weight 440.42
-
Formula C24H30BrN3
-
SMILES
C12=NC3=C(CCCC3)C(NCCCCCC[N+]4=CC=CC=C4)=C1C=CC=C2.[Br-]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Transepithelial/transendothelial electrical resistance assay
TEER measures electrical resistance across epithelial or endothelial monolayers cultured on permeable supports, and the readout reflects ionic conductance through the cell barrier, especially the paracellular pathway regulated by junctional integrity. TEER can be measured without destroying the monolayer and is commonly used before or during transport, permeability, barrier-disruption, and barrier-maturation experiments. TEER values are influenced by biological maturation and technical conditions; reported factors include temperature, medium formulation, passage number, electrode geometry, membrane properties, and junctional length during early monolayer maturation. Therefore, TEER should be interpreted with blank-insert subtraction, area normalization, repeated readings, and, when possible, orthogonal barrier readouts such as FITC-dextran flux or tight-junction staining.
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)